Otsuka : Notice regarding Postponement of the Announcement of Consolidated Financial Results for FY2020 First Quarter (23KB)
April 20, 2020 at 02:06 am EDT
Share
April 20, 2020
Company Name
Otsuka Holdings Co., Ltd.
Name of Representative
Tatsuo Higuchi
President and Representative Director, CEO
Code Number
4578, First Section of the Tokyo Stock
Exchange
Contact
Yuji Kogure
Director, Investor Relations Department
(Phone: +81-3-6361-7411)
Notice regarding Postponement of the Announcement of Consolidated Financial Results for
FY2020 First Quarter
Otsuka Holdings Co., Ltd. (the "Company") announces that the Company has decided to postpone the announcement of the Consolidated Financial Results for the first quarter ended March 31, 2020, from May 14, 2020 to May 28, 2020. Details are as follows:
1. Postponement of the Announcement of Consolidated Financial Results for FY2020 First Quarter
The Company has decided to postpone the announcement of the Consolidated Financial Results for the first quarter of FY2020 (January 1 through March 31, 2020) to May 28, 2020 from the initial schedule of May 14, 2020.
2. Reasons for the Postponement
Due to the worldwide spread of the novel coronavirus disease (COVID-19), a national emergency declaration has been issued in Japan and lockdowns (urban blockages) and curfews have been imposed in many countries of the world. Under these circumstances, there have been a delay in account closing procedures and other operations of the Otsuka group in Japan and overseas. In consideration of the situation, the Company has decided to postpone the announcement schedule for the Consolidated Financial Results for the first quarter of FY2020 ended March 31, 2020.
3. Current situation
In order to prevent the spread of COVID-19 and maintain business continuity, the Otsuka group is taking measures to ensure the health and safety of employees, such as telecommuting and staggered working hours.
Attachments
Original document
Permalink
Disclaimer
Otsuka Holdings Co. Ltd. published this content on 20 April 2020 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 20 April 2020 06:05:10 UTC
Otsuka Holdings Co, Ltd. is a holding company organised around 4 areas of activity:
- manufacture and sale of pharmaceutical products (65.2% of sales): prescription drugs and intravenous solutions mainly for the treatment of central nervous system disorders, cancer, cardiovascular, gastrointestinal and ophthalmic diseases. In addition, the group sells diagnostic products and medical devices;
- manufacture and sale of nutraceutical products (25.1%): functional foods and beverages, OTC products, nutritional supplements;
- production of mineral waters, beverages and foods (2.1%);
- other (7.5%): manufacture of functional chemicals and fine chemicals, provision of logistics services, manufacture of electronic products, etc.
Net sales by source of income are divided between sales of products (93.8%), sales of licences and royalties (1.8%) and other (4.4%).
Net sales are distributed geographically as follows: Japan (43.2%), North America (34%),
OTSUKA HOLDINGS CO., LTD. 
